ArticleRapid communications in mass spectrometry : RCM2026
LC-HRMS-Based Metabolic Profiling of the REV-ERB Agonist SR9009 in Camel Liver Homogenate and Cunninghamella elegans for Anti-Doping Analysis.
Article in Rapid communications in mass spectrometry : RCM, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleSR9009 is a synthetic REV-ERB agonist with potential performance-enhancing properties and is included on the World Anti-Doping Agency (WADA) Prohibited List for human sport. Its potential misuse has also raised concerns in animal sports, particularly equine and camel racing. Although SR9009 metabolism has been investigated in human and equine models, its metabolic fate in racing camels (Camelus dromedarius) remains unclear. Characterizing its biotransformation pathways and identifying suitable biomarkers are essential for developing reliable anti-doping screening strategies for camel racing.
methodsAn in vitro metabolic study was conducted using camel liver homogenate and the fungal model Cunninghamella elegans. Metabolites were characterized using liquid chromatography-high-resolution mass spectrometry (LC-HRMS). Putative structural elucidation was achieved through accurate mass measurements of precursor and product ions. Diagnostic fragmentation pathways were established using collision-induced dissociation (CID) tandem mass spectrometry (MS/MS), enabling the systematic identification of metabolic modifications based on characteristic fragment ions and neutral losses.
resultsSeventeen Phase I metabolites of SR9009 were identified. Major biotransformation pathways included N-dealkylation, mono-hydroxylation, di-hydroxylation, and combinations thereof. The N-dealkylated metabolite was the predominant metabolite detected in both camel liver homogenate and Cunninghamella elegans, indicating its suitability as a primary analytical target for anti-doping screening. No Phase II metabolites were detected under the experimental conditions employed. Putative structural assignments were supported by characteristic high-resolution tandem mass spectral fragmentation patterns.
conclusionsThis study provides the first comprehensive metabolic profile of SR9009 in a camel-specific in vitro model. The identification of 17 Phase I metabolites, particularly the predominant N-dealkylated derivative, provides valuable analytical targets for doping control. These findings establish a metabolic foundation for future in vivo studies to determine pharmacokinetics and detection windows in racing camels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.